ClinicalTrials.gg
CompletedNCT01328756Updated Jun 10, 2021Results posted

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 4 interventional study of Lisdexamfetamine dimesylate in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Shire. Completed at 35 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
314
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
7th of 51
314 · median 48
Started
2011
with 2 others
Phase 4
23 of 51
none open now
Registered
30th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 7th largest by enrollment, is one of 3 that started in 2011, is one of 23 in phase 4, and was the 30th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

While the Lisdexamfetamine Dimesylate (SPD489) clinical program has studied the efficacy, safety, and tolerability of SPD489 in treating core symptoms of ADHD in children and adolescents aged 6-17 years and adults aged 18-55 years, the majority of these studies have been of short duration - up to 8 weeks.

A number of long-term studies have been undertaken (up to 1 year) and these have confirmed the safety and ongoing efficacy in this patient population.

In order to run a study with investigational medication within Poland the study changed to a Phase 3 rather than a Phase 4 study in that country. Please note that the study number remains as SPD489-404.

Study SPD489-404 has been designed to further evaluate the long-term effects of SPD489 in children and adolescents over a 2-year treatment period.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder (ADHD)

Keywords

  • ADHD
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For subjects who participated in another SPD489 study (SPD489-317, SPD489-325, or SPD489 326):

  • Subject is a male or female aged 6-17 years.
  • Subject participated in SPD489-317, completed 9 weeks of treatment, and completed the 1 week post-treatment safety follow-up visit.

For subjects who have not participated in another SPD489 study:

  • Subject is a male or female aged 6-17 years.
  • Subject must meet criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation.

For all subjects:

  • Subject has a Baseline ADHD-RS-IV total score greater than or equal to 28.
  • Subject, who is female of (FOCP), must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test, and a negative urine pregnancy test at Baseline, be non-lactating and agree to comply with any applicable requirements of the protocol.
  • Subject and parent/LAR are willing and able to comply with all the testing and requirements defined, including oversight of morning dosing. Specifically, the parent/LAR must be available upon awakening, at approximately 7:00 AM, to dispense the dose of Product for the duration of the study.
  • Subject aged greater than or equal to 18 years has a systolic blood pressure less than or equal to 139 mmHg and a diastolic blood pressure less than or equal to 89 mmHg.
  • Subject is able to swallow a capsule.

Exclusion criteria

Exclusion Criteria:

For subjects who participated in another SPD489 study (SPD489-317, SPD489-325, or SPD489 326):

  • Subject was terminated from a previous SPD489 study (SPD489-325 or SPD489 326) for protocol non-adherence and/or subject non-compliance and/or experienced a medication-related SAE or AE resulting in termination from the previous study.
  • Subject experienced any AEs in a prior SPD489 study (SPD489 317, SPD489-325, or SPD489-326) that, in the opinion of the Investigator, would preclude further exposure to SPD489.

For all subjects:

  • Subject's symptoms are well-controlled on their currently prescribed ADHD medication with acceptable tolerability.
  • Subject has a positive urine drug result at Screening.
  • Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder (such as Post Traumatic Stress Disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder) or other symptomatic manifestations, such as agitated states, marked anxiety, or tension.
  • Subject has taken another Product or taken part in a clinical study with the exception of a prior SPD489 study (SPD489-317, SPD489 325, or SPD489 326) within 30 days prior to Screening.
  • Subject weighs less than 22.7 kg (50 lbs).
  • Subject is significantly overweight.
  • Subject has a conduct disorder. Oppositional defiant disorder is not exclusionary.
  • Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject.
  • Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator
  • Subject has glaucoma.
  • Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
  • Subject has any clinically significant abnormality.
  • Subject has any clinically significant laboratory abnormalities.
  • Subject has a documented allergy, , or intolerance to any active ingredient or in SPD489.
  • Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with criteria.
  • Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, a current diagnosis of Tourette's Disorder, or a known family history of Tourette's Disorder. Subject has a history of tics that is judged by the Investigator to be exclusionary.
  • Subject has a known history of symptomatic cardiovascular or cerebrovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  • Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  • Subject has a medical condition, other than ADHD, that requires treatment with medications that have central nervous system effects and/or affect performance. Stable use of anticholinergic or theophylline bronchodilators is not exclusionary.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine Dimesylate

    Drug: Lisdexamfetamine dimesylate

Interventions

  • Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years

    Also known as: Vyvanse, SPD489, LDX

06

What researchers measure

Primary outcomes

  1. Number of Participants With All Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. It included both serious and non-serious adverse event. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were defined as treatment-emergent if they started or worsened during the period between the day of a participant's first dose of investigational product in this study and the 3 days following cessation of treatment.

    Time frame: Baseline up to 3 days after the last dose of study treatment (up to 2 years)

  2. Change From Baseline in Pulse Rate at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  3. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  4. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  5. Change From Baseline in Body Weight at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  6. Change From Baseline in Height at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  7. Change From Baseline in Body Mass Index (BMI) at Last On-treatment Assessment (LOTA)

    BMI was calculated as (weight \[kilogram\] per height \[square meter\]).

    Time frame: Baseline (Week 0), LOTA (Week 104)

  8. Change From Baseline in Heart Rate at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  9. Change From Baseline in QT Interval at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  10. Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Last On-treatment Assessment (LOTA)

    Time frame: Baseline (Week 0), LOTA (Week 104)

  11. Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRSC) Total Scores at Last On-treatment Assessment (LOTA)

    The BPRS-C that was designed to provide a characterization of the child and adolescent psychopathology, was used to monitor participant's safety. The BPRS-C assessed 7 independent factors (3 items each), for a total of 21 items that represented behavioural disorders, depression, thinking disturbance, psychomotor excitation, withdrawal retardation, anxiety, and organicity. Each item was rated using a 7-point scale including 0 (not present), 1 (very mild), 2 (mild), 3 (moderate), 4 (moderately severe), 5 (severe), and 6 (extremely severe). Total score is the sum of each item score; range from 0 to 126. Higher score indicated worse psychology.

    Time frame: Baseline (Week 0), LOTA (Week 104)

Secondary outcomes

  1. Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Last On-treatment Assessment (LOTA)

    ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria, completed by the Investigator. Each item was scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items were grouped into 2 sub-scales: hyperactivity/impulsivity (even number items 2-18 with score range of 0 to 27) and inattention (odd number items 1-17 with score range of 0 to 27). Higher scores depicted worse symptoms.

    Time frame: Baseline (Week 0), LOTA (Week 104)

  2. Number of Participants With Clinical Global Impression-Global Improvement (CGI-I) at Last On-treatment Assessment (LOTA)

    The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-I was a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), evaluated by the Investigator.

    Time frame: LOTA (Week 104)

  3. Number of Participants With Clinical Global Impression-Severity of Illness (CGI-S) at Last On-treatment Assessment (LOTA)

    The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-S was a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants), evaluated by the Investigator.

    Time frame: LOTA (Week 104)

07

Results

Posted Aug 6, 2015
Limitations and caveats
Since this study is an open-label trial, results should be interpreted with caution.

Participant flow

This study enrolled participants from 3 antecedent studies (SPD489-317 \[NCT01106430\], SPD489-325 \[NCT00763971\], and SPD489-326 \[NCT00784654\]), or directly enrolled.

Participant flow — Overall Study
MilestoneLisdexamfetamine Dimesylate
Started314
Completed191
Not completed123
Withdrew: Protocol violation4
Withdrew: Adverse event39
Withdrew: Lack of efficacy5
Withdrew: Withdrawal by subject41
Withdrew: Lost to follow-up5
Withdrew: Other29

Outcome measures

PrimaryNumber of Participants With All Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. It included both serious and non-serious adverse event. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were defined as treatment-emergent if they started or worsened during the period between the day of a participant's first dose of investigational product in this study and the 3 days following cessation of treatment.

Time frame:
Baseline up to 3 days after the last dose of study treatment (up to 2 years)
Reported as:
Number · participants
Number of Participants With All Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
participantsLisdexamfetamine Dimesylate
Any TEAE282
Serious TEAE28
PrimaryChange From Baseline in Pulse Rate at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · beats per minute
Change From Baseline in Pulse Rate at Last On-treatment Assessment (LOTA)
beats per minuteLisdexamfetamine Dimesylate
Change From Baseline in Pulse Rate at Last On-treatment Assessment (LOTA)7 ± 11.6
PrimaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Last On-treatment Assessment (LOTA)
mmHgLisdexamfetamine Dimesylate
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Last On-treatment Assessment (LOTA)3.2 ± 9.05
PrimaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Last On-treatment Assessment (LOTA)
mmHgLisdexamfetamine Dimesylate
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Last On-treatment Assessment (LOTA)3.4 ± 10.33
PrimaryChange From Baseline in Body Weight at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · kilogram(s)
Change From Baseline in Body Weight at Last On-treatment Assessment (LOTA)
kilogram(s)Lisdexamfetamine Dimesylate
Change From Baseline in Body Weight at Last On-treatment Assessment (LOTA)2.1 ± 5.83
PrimaryChange From Baseline in Height at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · centimeter(s)
Change From Baseline in Height at Last On-treatment Assessment (LOTA)
centimeter(s)Lisdexamfetamine Dimesylate
Change From Baseline in Height at Last On-treatment Assessment (LOTA)6.1 ± 4.9
PrimaryChange From Baseline in Body Mass Index (BMI) at Last On-treatment Assessment (LOTA)

BMI was calculated as (weight \[kilogram\] per height \[square meter\]).

Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · kilogram per square meter
Change From Baseline in Body Mass Index (BMI) at Last On-treatment Assessment (LOTA)
kilogram per square meterLisdexamfetamine Dimesylate
Change From Baseline in Body Mass Index (BMI) at Last On-treatment Assessment (LOTA)-0.5 ± 1.72
PrimaryChange From Baseline in Heart Rate at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Last On-treatment Assessment (LOTA)
beats per minuteLisdexamfetamine Dimesylate
Change From Baseline in Heart Rate at Last On-treatment Assessment (LOTA)7.1 ± 13.51
PrimaryChange From Baseline in QT Interval at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · milliseconds
Change From Baseline in QT Interval at Last On-treatment Assessment (LOTA)
millisecondsLisdexamfetamine Dimesylate
Change From Baseline in QT Interval at Last On-treatment Assessment (LOTA)-10.3 ± 23.53
PrimaryChange From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Last On-treatment Assessment (LOTA)
Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · milliseconds
Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Last On-treatment Assessment (LOTA)
millisecondsLisdexamfetamine Dimesylate
Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Last On-treatment Assessment (LOTA)-0.6 ± 15.24
PrimaryChange From Baseline in Brief Psychiatric Rating Scale for Children (BPRSC) Total Scores at Last On-treatment Assessment (LOTA)

The BPRS-C that was designed to provide a characterization of the child and adolescent psychopathology, was used to monitor participant's safety. The BPRS-C assessed 7 independent factors (3 items each), for a total of 21 items that represented behavioural disorders, depression, thinking disturbance, psychomotor excitation, withdrawal retardation, anxiety, and organicity. Each item was rated using a 7-point scale including 0 (not present), 1 (very mild), 2 (mild), 3 (moderate), 4 (moderately severe), 5 (severe), and 6 (extremely severe). Total score is the sum of each item score; range from 0 to 126. Higher score indicated worse psychology.

Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · scores on a scale
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRSC) Total Scores at Last On-treatment Assessment (LOTA)
scores on a scaleLisdexamfetamine Dimesylate
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRSC) Total Scores at Last On-treatment Assessment (LOTA)-10.3 ± 9.64
SecondaryChange From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Last On-treatment Assessment (LOTA)

ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria, completed by the Investigator. Each item was scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items were grouped into 2 sub-scales: hyperactivity/impulsivity (even number items 2-18 with score range of 0 to 27) and inattention (odd number items 1-17 with score range of 0 to 27). Higher scores depicted worse symptoms.

Time frame:
Baseline (Week 0), LOTA (Week 104)
Reported as:
Mean · Scores on a scale
Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Last On-treatment Assessment (LOTA)
Scores on a scaleLisdexamfetamine Dimesylate
Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Last On-treatment Assessment (LOTA)-25.8 ± 11.1
Statistical analysis
  • Lisdexamfetamine Dimesylate · t-test, 2 sided · p = < 0.001
SecondaryNumber of Participants With Clinical Global Impression-Global Improvement (CGI-I) at Last On-treatment Assessment (LOTA)

The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-I was a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), evaluated by the Investigator.

Time frame:
LOTA (Week 104)
Reported as:
Number · participants
Number of Participants With Clinical Global Impression-Global Improvement (CGI-I) at Last On-treatment Assessment (LOTA)
participantsLisdexamfetamine Dimesylate
Very much improved141
Much improved92
Minimally improved28
No change20
Minimally worse13
Much worse5
Very much worse0
SecondaryNumber of Participants With Clinical Global Impression-Severity of Illness (CGI-S) at Last On-treatment Assessment (LOTA)

The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-S was a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants), evaluated by the Investigator.

Time frame:
LOTA (Week 104)
Reported as:
Number · participants
Number of Participants With Clinical Global Impression-Severity of Illness (CGI-S) at Last On-treatment Assessment (LOTA)
participantsLisdexamfetamine Dimesylate
Normal, not all ill73
Borderline mentally ill97
Mildly ill67
Moderately ill39
Markedly ill17
Severely ill4
Among the most extremely ill participants2

Adverse events

Collected over Baseline up to 3 days after the last dose of study treatment (up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate—28/314 (8.9%)250/314 (79.6%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventLisdexamfetamine Dimesylate
SyncopeNervous system disorders6/314
AppendicitisInfections and infestations3/314
PyelonephritisInfections and infestations2/314
LymphadenitisBlood and lymphatic system disorders1/314
ArrhythmiaCardiac disorders1/314
Abdominal painGastrointestinal disorders1/314
Dental cariesGastrointestinal disorders1/314
DisbacteriosisGastrointestinal disorders1/314
Condition aggravatedGeneral disorders1/314
PyrexiaGeneral disorders1/314
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLisdexamfetamine Dimesylate
Decreased appetiteMetabolism and nutrition disorders170/314
NasopharyngitisInfections and infestations73/314
HeadacheNervous system disorders68/314
Weight decreasedInvestigations63/314
InsomniaPsychiatric disorders60/314
Initial insomniaPsychiatric disorders38/314
IrritabilityGeneral disorders36/314
NauseaGastrointestinal disorders31/314
PyrexiaGeneral disorders31/314
Abdominal painGastrointestinal disorders29/314

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lisdexamfetamine Dimesylate
Mean11.4 ± 2.88
Sex: Female, Male
Sex: Female, Male(Participants)Lisdexamfetamine Dimesylate
Female64
Male250
Clinical Global Impressions - Severity of Illness (CGI-S) Rating
Clinical Global Impressions - Severity of Illness (CGI-S) Rating(Participants)Lisdexamfetamine Dimesylate
Normal, not all ill0
Borderline mentally ill0
Mildly ill1
Moderately ill69
Markedly ill152
Severely ill81
Among the most extremely ill participants11
Body Weight
Body Weight(kilogram(s))Lisdexamfetamine Dimesylate
Mean46.13 ± 16.434
Height
Height(centimeters)Lisdexamfetamine Dimesylate
Mean152.29 ± 16.633
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter)Lisdexamfetamine Dimesylate
Mean19.22 ± 3.389
Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV): Total Score
Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV): Total Score(scores on a scale)Lisdexamfetamine Dimesylate
Mean41.1 ± 7.03
ADHD-RS-IV: Inattention Subscale Score
ADHD-RS-IV: Inattention Subscale Score(scores on a scale)Lisdexamfetamine Dimesylate
Mean22.1 ± 3.52

1 further baseline measures are reported on the registry.

08

Study locations

35 sites
  • ZNA Antwerpen, Commandant Weynsstraat 165 Campus Hoge Beuken
    Hoboken, Antwerp 2660, Belgium
  • Afdeling Psychiatrie
    Leuven, B-3000, Belgium
  • Albert-Ludwigs-Universität Freiburg
    Freiburg, Baden-Wuerttemberg 79104, Germany
  • Zentralinstitut für Seelische Gesundheit Mannheim
    Mannheim, Baden-wuerttemberg 68159, Germany
  • Schwerpunktpraxis für Entwicklung und Lernen
    Bamberg, Bayern 96047, Germany
  • Medizinisches Studienzentrum Würzburg
    Wurzburg, Bayern 97070, Germany
  • Praxis Dr.Christian Wolff
    Hagen, Nordrhein-Westfalen 58093, Germany
  • Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Praxis Dr. med. Friedrich Kaiser und Dr. med. Ingrid Marinesse
    Hamburg, 22415, Germany
  • Gyermek es Ifjusagpszichiatriai Szakrendeles es Gondozo Veress E. u. 2.
    Pecs, Baranya H-7633, Hungary
  • Szegedi Tudomanyegyetem, Gyermek- es Ifjusagpszichiatriai Osztaly Boldogasszony sgt. 15
    Szeged, Csongrad H-6720, Hungary
  • Vadaskert Korhaz es Szakambulancia, Gyermek es Ifjusagpszichiatria Huvosvolgyi ut 116
    Budapest, H-1021, Hungary
  • Pandy Kalman Korhaz, Gyermekpszichiatria Semmelweis u.1.
    Gyula, H-5700, Hungary
  • Azienda Ospedaliero-Universitaria di Cagliari
    Cagliari, 09124, Italy
  • Azienda Ospedaliera Universitaria Policlinico G. Martino
    Messina, 98125, Italy
  • Academisch Ziekenhuis Maastricht
    Heerlen, Limburg 6419XZ, Netherlands
  • Szpital Uniwersytecki im. dr. Antoniego Jurasza w Bydgoszczy
    Bydgoszcz, Kujawsko-pomorskie 85-094, Poland
  • Wojewodzki Osrodek Lecznictwa Psychiatrycznego W Toruniu
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny
    Warszawa, Mazowieckie 00-576, Poland
  • Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu"
    Timisoara, Timis 300011, Romania
  • Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia"
    Bucuresti, 41914, Romania
  • Spitalul Clinic de Psihiatrie Socola
    Iasi, Romania
  • Hospital Son Llàtzer
    Palma de Mallorca, Baleares 07198, Spain
  • Hospital Sant Joan de Deu, Servicio de Psiquiatria Infantil Passeig Sant Joan de Deu, 2 Esplugues de Llobregat
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Mutua de Terrassa, Centro de Salud Mental Cap Rambla Psiquiatria Infantil Placa Doctor Robert, 5
    Terrassa, Barcelona 08221, Spain
  • Hospital Maritimo de Torremolinos
    Torremolinos, Malaga 29620, Spain
  • Clinica Universitaria de Navarra, Unidad de Psiquiatría Infantil y Adolescente, Dept. de Psiquiatria y Psicologia Medica Avenida Pio XII 36 Apartado 4209 Pamplona
    Pamplona, Navarra 31008, Spain
  • Hospital Univeritario de Canarias, Consultas Externas de Psiquiatria Ofra l La Cuesta s/n San Cristobal de la Laguna Laguna Santa Cruz
    San Cristóbal de la Laguna, Santa CRUZ DE Tenerife 38320, Spain
  • Complejo Hospitalario Universitario de Badajoz
    Badajoz, 06010, Spain
  • Hospital Clinic I Provincial de Barcelona
    Barcelona, 08036, Spain
  • Child Neuropsychiatry Centre The Queen Silvia Children's Hospita Otterhallegatan 12A
    Goteburg, 41118, Sweden
  • Barn och Ungdomsmedicin klinik Molnlycke Ekdalavagen 2 Box 9
    Molnlycke, 43530, Sweden
  • Paediatric Neurology Children's Hospital in Huddinge
    Stockholm, 14186, Sweden
  • Thurrock Hospital
    Grays, England RM16 2PX, United Kingdom
  • University of Dundee, Centre for Child Health 19 Dudhope Terrace Scotland
    Dundee, Scotland DD3 6HH, United Kingdom
09

References and documents

Publications

  • Banaschewski T, Johnson M, Nagy P, Otero IH, Soutullo CA, Yan B, Zuddas A, Coghill DR. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2018 May;32(5):455-467. doi: 10.1007/s40263-018-0514-8. PubMed 29790103 ↗
  • Coghill DR, Banaschewski T, Bliss C, Robertson B, Zuddas A. Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate. CNS Drugs. 2018 Jan;32(1):85-95. doi: 10.1007/s40263-017-0487-z. PubMed 29383572 ↗
  • Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B, Caballero B, Zuddas A. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. CNS Drugs. 2017 Jul;31(7):625-638. doi: 10.1007/s40263-017-0443-y. PubMed 28667569 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Sep 2014, 38 months.

Results were first posted in Aug 2015, 10 months after primary completion.

Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2011
First posted
Apr 5, 2011
StartActual
Jul 7, 2011
Primary completionActual
Sep 30, 2014
CompletionActual
Sep 30, 2014
Results first posted
Aug 6, 2015
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01328756
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Apr 5, 2011
Start date
Jul 7, 2011
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014
Results posted
Aug 6, 2015
Last update
Jun 10, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion